TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prothena ( (PRTA) ) has provided an announcement.
On November 19, 2025, Prothena Corporation held an extraordinary general meeting where shareholders approved a proposal to reduce the company’s capital to create distributable reserves. This decision is expected to impact the company’s financial flexibility and potentially enhance shareholder value.
The most recent analyst rating on (PRTA) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Spark’s Take on PRTA Stock
According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.
Prothena’s overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flows. Technical analysis shows positive momentum, but valuation metrics are weak due to ongoing losses. The absence of recent earnings commentary adds uncertainty.
To see Spark’s full report on PRTA stock, click here.
More about Prothena
Prothena Corporation plc is a biotechnology company focused on the discovery and development of novel therapies for diseases involving protein misfolding and cell adhesion.
Average Trading Volume: 740,981
Technical Sentiment Signal: Sell
Current Market Cap: $551.8M
For a thorough assessment of PRTA stock, go to TipRanks’ Stock Analysis page.